Indiana Senate Bill 282 (SB 282), introduced January 12, 2026, is a combined proposal aimed at two parts of the market regulators increasingly treat as one continuous risk chain: (i) compounded-drug sourcing and documentation and (ii) outpatient medical spa delivery models offering injectable products. If enacted in anything close to its introduced form, SB 282 would tighten expectations for bulk drug substance use, impose rapid record-production timelines, require semiannual state reporting on compounding risks (including marketing/telehealth-related categories), and create a Board of Pharmacy registration and oversight regime for medical spas beginning January 1, 2027. It will be the first time we’re aware of that any state has required a MedSpa to obtain pharmacy license for just selling peptides.
What SB 282 is really doing
SB 282 is not just “a pharmacy bill” and not just “a medspa bill.” It is an attempt to regulate the outpatient ecosystem where compounded drugs (including peptides) are promoted, distributed, and administered. The bill directs the Indiana Department of Health to publish semiannual reports on compounding oversight and risks and indicates that the state is looking beyond the compounding site itself, reaching retail/outpatient settings that handle, store, administer, dispense, distribute, or use compounded drugs, including 503A pharmacies, 503B outsourcing facilities, and medical spas.
That same reporting mandate explicitly contemplates disciplinary actions relating to improper marketing, advertising, or promotion of compounding drugs and telehealth services. Indiana is framing patient safety and “consumer-facing” promotion as inseparable from compounding oversight.
Why compounding pharmacies and suppliers should care
SB 282 creates a new Indiana Code chapter titled “Drugs: Restrictions on Bulk Drug Substances.” It defines “compounding” broadly (including mixing, diluting, pooling, reconstituting, or otherwise altering a drug or bulk drug substance) and then states a person may not engage in compounding unless specified requirements are met. Those requirements include USP/NF monograph and USP chapter-related criteria where applicable, pharmaceutical grade expectations, and documentation expectations such as certificates of analysis with specified content. Given the popularity of peptides and the movement of MedSpas into the wellness space, the Bill is a clear shot by Pharma into compounded competition. It essentially knocks MedSpas out of the peptide space.
One introduced provision is likely to draw intense scrutiny if it remains: the bill requires that “any bulk drug substance used has been reviewed as part of a new drug application and approved” under 21 U.S.C. § 355. Whether that language is amended later or not, its inclusion reflects legislative appetite to narrow what ingredients may be treated as acceptable for compounding in Indiana.
Just as important operationally, SB 282 is drafted to accelerate oversight. The bill imposes recordkeeping and production obligations with a short fuse. It requires covered parties to furnish specified records to the Indiana Board of Pharmacy not later than one business day after receipt of a request, unless the Board indicates a reasonable alternative timeframe; it also includes a parallel obligation for a person that engages in compounding to provide records within one business day or a Board-determined reasonable time.
A key precision point for industry: this obligation is not framed as “pharmacies only.” The introduced text uses “any person” in the sale/transfer/distribution recordkeeping provision and separately addresses “a person that engages in compounding.” That drafting choice increases the likelihood that Indiana could apply documentation expectations broadly across the outpatient chain, depending on enforcement posture and final statutory language.
Why medical spas and wellness clinics should care
SB 282 defines “medical spa” in a way that captures many modern wellness and longevity models, not just facility that calls itself a “MedSpa.” “A facility or practice that provides medical healthcare services, uses prescription drugs for IV/IM/subcutaneous delivery, and holds itself out as focused on cosmetic or lifestyle treatments (including weight loss, wellness, and longevity)”, with examples such as botulinum toxin injections, hormone therapies, and parenteral nutrient therapies.
Under the proposed law, beginning January 1, 2027, medical spas must be registered with the Indiana Board of Pharmacy to do business in Indiana, and the Board must maintain a public database of registration information and disciplinary actions (with redaction of certain health information). The bill also requires each medical spa to designate a “responsible person” who must be physically present for sufficient time to ensure compliance with the bill.
SB 282 further requires reporting to the Board of “serious adverse events” not later than five days after occurrence, with specified information including the prescription medication involved and relevant medical records. For operators, this is a concrete shift away from loosely governed “provider network” models and toward a named-accountability framework with mandatory incident reporting.
Key Takeaways
Stakeholders may consider reviewing bulk drug substance sourcing and documentation narratives, assessing whether records could realistically be produced within a one-business-day timeframe, and evaluating whether outpatient partners, particularly medical spas and wellness clinics, are structured to withstand Board-level registration, accountability, and adverse-event reporting requirements. At a minimum, businesses operating in or supplying Indiana should closely monitor SB 282 as it moves through committee review and amendment. The most consequential language, definitions, ingredient criteria, and enforcement hooks, often evolves during that process, and early awareness provides the best opportunity to anticipate compliance shifts before they become binding obligations.
SB 282 is proposed legislation, but if passed it would further cement the state’s clear alignment with the pharmaceutical industry. Like the state’s proposed Safe Act” (a/k/a “Lilly’s Law”), Indiana’s full commitment to protecting Pharma’s compounded GLP market share couldn’t be more transparent, even at the cost of access and affordability. Make no mistake: the latest Indiana proposed law is pure economic protectionism. And it cares not for its impact on price or access.
The real question is how far Indiana will go to embrace its Pharma overlords. The first step (Safe Act) essentially puts the compound pharmacy industry out of business vis a vis the GLP market. This latest proposed law now aims directly at wellness based businesses that use compounded GLPs to help their wellness clients.
